

**DISCLOSURE OF MOVEMENT OF 1% OR MORE IN SUBSTANTIAL HOLDING OR CHANGE IN NATURE OF RELEVANT INTEREST, OR BOTH**

*Sections 277 and 278, Financial Markets Conduct Act 2013*

**TO:** NZX Limited

and

**TO:** Finzsoft Solutions Limited ("**FIN**")

Relevant event being disclosed: Change in nature of relevant interest

Date of relevant event: 30 October 2019

Date this disclosure made: 30 October 2019

Date last disclosure made: 28 August 2019

**Substantial product holder giving disclosure**

Full name(s): HGH (ICT Investments No. 2) Limited ("**HGH2**")

**Summary of previous substantial holding**

Class of quoted voting products: Ordinary shares

Summary for: HGH2

For **this** disclosure:

(a) total number held in class: 3,689,205

(b) total in class: 8,808,830

(c) total percentage held in class: 41.88%

For **last** disclosure:

(a) total number held in class: 3,689,205

(b) total in class: 8,808,830

(c) total percentage held in class: 41.88%

## Details of transactions and events giving rise to relevant event

Details of the transactions or other events requiring disclosure:

On 28 August 2019, HGH2, Silverlake Axis Ltd ("SAL") and Silverlake HGH Limited ("SHGH") entered a deed of settlement and implementation ("Deed"), pursuant to which SHGH agreed to sell the shares it holds in FIN to each of SAL and HGH2 in proportion to their respective proportionate shareholding in SHGH, at fair market value.

The acquisition of the shares in FIN held by SHGH, by each of SAL and HGH2, was subject to the approval of the shareholders of FIN by ordinary resolution, for the purposes of rule 7(c) of the Takeovers Code. A copy of the Deed was attached to HGH2's substantial product holder notice dated 28 August 2019.

On 29 October 2019, FIN shareholders approved SHGH to transfer FIN shares to SAL and HGH2 under the Deed. Accordingly, pursuant to the Deed, on 30 October 2019, SHGH transferred 3,689,205 FIN shares to HGH2.

## Details after relevant event

Details for:

HGH2

Nature of relevant interest(s):

Legal and beneficial owner of 3,689,205 ordinary shares in FIN.

For that relevant interest:

- |     |   |           |
|-----|---|-----------|
| (a) | number held in class:                               | 3,689,205 |
| (b) | percentage held in class:                           | 41.88%    |
| (c) | current registered holder(s):                       | SHGH      |
| (d) | registered holder(s) once transfers are registered: | HGH2      |

## Additional information

Address(es) of substantial product holder(s):

59a Western Avenue, Omokoroa, Tauranga, 3172, New Zealand

Contact details:

Andrew Holliday  
Phone: +64 21 355 492  
Email: Andrew.Holliday@finzsoft.com

Name of any other person believed to have given, or believed to be required to give, a disclosure under the Financial Markets Conduct Act 2013 in relation to the financial products to which this disclosure relates:

Silverlake Axis Ltd  
Silverlake HGH Limited

**Certification**

I, Andrew Alexander Holliday, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.